P1 · Healthcare / diagnostics / care delivery · 5–15 yearsPublished investment brief

Women's health formalization

Historically underdiagnosed and under-reimbursed women's health conditions are being converted into defined, coverage-backed care categories by a convergent policy, clinical-evidence and reimbursement shift dated to 2025-2026. The most direct listed exposure sits in fertility benefits (Progyny), fertility/women's-health devices and consumables (CooperCompanies' CooperSurgical), and women's diagnostics and imaging (Hologic), where recurring, reimbursement-linked revenue is already visible. The theme is investable primarily through differentiated players with proprietary assets and employer/payer distribution; for many large mapped incumbents women's health is a minority of revenue, so the case is selective rather than broad-basket.

Ask follow-up research

Reviewed research brief · researched 2026-07-22 · not an individual investment recommendation

Sourced indicators: 8
Mapped companies: 13
Scenarios: 3
Cited sources: 12
Thesis breaks: 5
Open questions: 7

Investment case

Why this theme may be investable

Historically underdiagnosed conditions affecting women are becoming formally defined care categories with dedicated diagnostics, therapeutics, devices and specialist networks. Better clinical recognition, sex-specific data (NIH Sex-as-a-Biological-Variable policy and the NIH-Wide Strategic Plan for Research on the Health of Women 2024-2028), and expanding reimbursement (state IVF/fertility mandates, federal employer-benefit pathways, FDA label liberalization) can convert neglected conditions into reimbursed, recurring-revenue markets. Value accrues to firms holding proprietary assays, installed imaging bases, brand/patent-protected therapeutics, or employer distribution moats.

Why now

Multiple dated 2025-2026 catalysts formalize the theme now: a February 2025 federal executive order directing policies to protect and expand IVF access; October 2025 federal actions creating a pathway for employers to offer fertility benefit packages and negotiating lower fertility-drug pricing; California SB 729 requiring large-group IVF coverage effective January 1, 2026; the November 2025 FDA removal of the boxed warning on menopause hormone-therapy products; FY2026 Senate Appropriations directing a USD 400 million NIH increase with report language prioritizing uterine fibroids and PCOS; and the April 2025 reversal of a proposed termination of Women's Health Initiative funding. Together these convert previously self-pay or neglected conditions into reimbursed categories, evidenced in recurring-revenue growth at Progyny and CooperSurgical.

Source of pricing power

Pricing power derives from (1) reimbursement/coverage formalization (state mandates, employer benefits, FDA labels) that shifts demand from discretionary self-pay to covered volume; (2) proprietary assets - validated molecular assays, AI-enabled imaging and large installed bases with switching costs; (3) brand and patent protection in contraception, menopause and endometriosis/fibroid therapeutics; (4) specialist scarcity (REIs, urogynecologists); and (5) employer distribution moats and high client retention for benefits managers and virtual platforms.

Duration and maturity

Horizon 5-15 years, consistent with the packet. Maturity is mixed: fertility benefits, molecular reproductive testing and virtual specialty care are early-to-mid growth; imaging and contraception are mature/cyclical; menopause therapeutics and pelvic-health devices are at an early policy-driven inflection. Overall the theme is in early-to-mid 'formalization', with reimbursement adoption the pacing variable.

Causal chain

How the change becomes cash flow

Clinical gaps and underdiagnosis in women's health become measurable as sex-specific evidence and NIH strategic focus (SABV policy; NIH-Wide Strategic Plan for Research on the Health of Women 2024-2028) expand.
Dedicated diagnostics, screening and care pathways emerge - NIPT and carrier screening, HPV/cervical cytology, AI mammography and breast ultrasound, fertility and pelvic-health devices, and virtual specialty care.
Reimbursement and policy formalize the categories: state IVF/fertility coverage mandates (25 states plus DC), a new federal pathway for employer fertility benefits, and FDA label liberalization (Nov 2025 removal of the menopause hormone-therapy boxed warning).
Employer and payer coverage expands the addressable insured pool, converting elective and self-pay demand into recurring, covered volume.
Specialist capacity and networks scale (fertility clinics/REIs, urogynecology, maternal care) while benefits managers and virtual platforms aggregate and route demand.
Focused products and networks gain adoption and pricing power via proprietary assays, installed base, brand/patent protection and employer distribution.
Neglected conditions mature into defined, investable markets - but returns concentrate in differentiated players while undifferentiated testing/device categories risk commoditization.

Market evidence

Dated, sourced indicators

Freshness is strong on policy (Feb 2025-Nov 2025 federal/state actions; FY2026 appropriations) and on the three highest-exposure listed names (Progyny Q1 2025 dated 2025-05-08; CooperCompanies fiscal Q2 2025 dated 2025-05-29; Hologic fiscal Q2 2025 dated 2025-04-30). Load-bearing policy claims are sourced to policy-tracking (MultiState) and advocacy (SWHR) secondary write-ups; the primary regulatory texts (FDA notice, state statutes, Federal Register, appropriations bill) are the recommended next-diligence upgrade. Market-size figures are secondary market-research estimates with wide dispersion. SEC.gov filings and several corporate newsrooms could not be retrieved by the fetch tool this session (HTTP 403), and the shared WebSearch budget was exhausted mid-task, limiting fresh primary financials for several diversified incumbents.

Market context: Third-party market-research estimates place the global women's health market at roughly USD 53-55 billion in 2025, projected to about USD 75 billion by 2033 (Grand View, ~5.1% CAGR) and about USD 92 billion by 2035 (Emergen, ~5.3% CAGR); the narrower 'femtech' segment is estimated between roughly USD 32 billion and USD 66 billion for 2025-2026 depending on definition. These are secondary estimates with wide dispersion and inconsistent scope. ( as of 2025)[10]

NIH investment in women's health research~USD 4.6 billion in FY2024 (~10% of the NIH appropriation per NIH reporting); an independent National Academies analysis found a lower and declining share - 7.9% (USD 3.4 billion of USD 43.7 billion) in FY2023, down from 9.7% in FY2013 USD / % of NIH budget
as of FY2023-FY2024 · United States[1]
State private-insurance fertility coverage mandates25 states plus Washington, D.C. require private insurance coverage for fertility care; over half of U.S. states introduced or carried over fertility-mandate legislation in 2026 states
as of 2026-04 · United States[3]
Progyny total revenue (Q1 2025)USD 324.0 million, +16.5% YoY; fertility benefit services revenue USD 206.4 million (+22%); full-year 2025 guidance USD 1.185-1.235 billion USD
as of 2025-03-31 · United States[8]
Progyny covered lives and clients (Q1 2025)~900,000 lives added in the most recent selling season; 532 clients; 16,200 ART cycles performed in the quarter (+9% YoY) lives / clients / cycles
as of 2025-03-31 · United States[8]
CooperCompanies CooperSurgical revenue (fiscal Q2 2025)CooperSurgical USD 332.7 million (+8%); of which fertility USD 126.9 million (+3%) and office & surgical/women's-health USD 205.8 million (+13%); FY2025 CSI guidance USD 1,347-1,359 million USD
as of 2025-04-30 · Global[7]
Hologic women's-health divisions (fiscal Q2 2025)Breast Health USD 356.2 million (-7.4% YoY, mammography capital-equipment weakness); GYN Surgical USD 162.5 million (+4.2%); Diagnostics USD 453.6 million (+0.8%; includes ThinPrep cervical cytology and Aptima HPV) USD
as of 2025-03-29 · Global[6]
FDA action on menopause hormone therapyFDA announced removal of the boxed ('black box') warning from menopause hormone-therapy products, particularly low-dose vaginal estrogen - a category-level regulatory liberalization
as of 2025-11 · United States[5]
FY2026 NIH appropriations and women's-health directivesSenate Appropriations approved a USD 400 million NIH increase (incl. +USD 20 million for NICHD) with report language prioritizing uterine fibroids and PCOS research USD
as of 2026 (FY2026 cycle) · United States[5]

Investment transmission

Who captures the economics

Business models

Bottlenecks and scarce assets

Financial transmission

Coverage formalization converts elective/self-pay demand into recurring, reimbursement-linked revenue: employer fertility benefits show up as high-retention recurring revenue with utilization upside (Progyny Q1 2025 revenue +16.5%, fertility services +22%), while state and federal mandates expand the insured pool. Diagnostics and device margins are driven by assay/consumable pull-through on installed bases, but capital-equipment cyclicality can depress near-term growth (Hologic Breast Health -7.4%). Genetic-testing cash flows depend on ASP versus volume as coverage broadens. Menopause and endometriosis/fibroid therapeutics gain from FDA/label liberalization but face loss-of-exclusivity erosion. Private care platforms' margins hinge on customer-acquisition-cost discipline; without it, care economics break.

Value chain

Where value is retained

Screening and diagnosis - imaging (mammography, breast ultrasound, AI)retains value
Installed base with switching costs and consumable/service pull-through; capital cycle is more volume-driven and cyclical (Hologic Breast Health -7.4% in fiscal Q2 2025).
Molecular and genetic reproductive testing (NIPT, carrier, HPV)uncertain
Value depends on reimbursement coverage and average selling prices; competition and payer pressure create commoditization risk despite proprietary content.
Women's-health therapeutics (contraception, menopause, endometriosis/fibroids)retains value
Retains value while brand/patent protected and while FDA/label tailwinds expand eligible populations; legacy/established brands are volume-only and face loss of exclusivity.
Fertility benefits managementretains value
Benefits manager captures recurring, high-retention employer revenue and network economics; the swing factor is covered-lives growth and take-rate durability against carrier in-sourcing.
Fertility and women's-health devices/consumablesretains value
Recurring consumables and coverage-linked devices retain value; hardware alone is more volume-only.
Care delivery, navigation and digital platformsuncertain
Value retention hinges on customer-acquisition-cost discipline versus retention and on payer willingness to pay; unproven unit economics is an explicit thesis-break risk.

Scenarios

Base, upside, and downside

base

Formalization continues incrementally. Fertility mandates expand state-by-state, the NIH strategic plan sustains a meaningful (if contested) women's-health research share, and fertility benefits, reproductive diagnostics and women's-health devices grow high-single-digit to mid-teens. Incumbents defend share via installed base and reimbursement while pure-plays compound but face rising competition; undifferentiated testing categories see ASP pressure.

Measurable triggers

Continued state mandate adoption and stable employer benefit demand
Progyny covered-lives and client growth in line with mid-teens revenue growth
CooperSurgical fertility reaccelerating toward mid-single-digit growth
Hologic diagnostics/GYN surgical offsetting breast-health capital softness

Likely beneficiaries: cmp-progyny; cmp-coopercompanies; cmp-hologic; cmp-organon

Likely losers: undifferentiated NIPT/carrier-screening providers facing ASP compression; lagging imaging capital-equipment vendors

upside

Policy inflection accelerates. A national employer fertility-benefit pathway plus broadening state and VA/veteran coverage step up the covered pool; the FDA menopause-warning removal and non-hormonal menopause launches expand the menopause addressable market; NIH directed funding (fibroids, PCOS) and calls for large transformational women's-health investment seed new categories; and digital platforms reach durable profitability. Recurring-revenue compounding broadens across the theme.

Measurable triggers

Federal employer fertility-benefit pathway drives a national coverage step-up
Successful non-hormonal menopause therapy launches and label expansions
Progyny/Maven covered-lives inflection and positive private funding marks
Directed NIH fibroid/PCOS funding catalyzes new diagnostic/therapeutic pipelines

Likely beneficiaries: cmp-progyny; cmp-maven-clinic; cmp-bayer; cmp-organon; cmp-axena-health

Likely losers: innovation laggards slow to build differentiated, coverage-backed offerings

downside

Reimbursement stalls and economics compress. State budget constraints and vetoes (e.g., a governor's veto of a broader Medicaid mandate) slow mandate expansion; Medicaid largely stays excluded; a downturn cuts elective fertility spend; carriers in-source fertility benefits, pressuring benefits-manager take-rates; NIPT/carrier screening commoditizes; imaging capital weakness persists; and private femtech customer-acquisition costs overwhelm care economics, forcing down rounds.

Measurable triggers

Fertility-mandate retreat or Medicaid exclusion; state fiscal pushback
Progyny covered-lives decline or client losses for two-plus quarters
Material ASP declines in reproductive testing signaling commoditization
Private femtech down rounds and elevated CAC versus retention

Likely beneficiaries: diversified incumbents with pricing power and low-cost testing platforms

Likely losers: cmp-progyny; cmp-maven-clinic; cmp-axena-health; sub-scale reproductive-testing providers

Valuation and cycle context: The theme spans a wide valuation and business-quality spectrum, which resists a single multiple. At one end sit higher-growth, reimbursement-linked pure-plays (Progyny grew Q1 2025 revenue 16.5% with full-year 2025 revenue guidance of USD 1.185-1.235 billion and positive adjusted EBITDA guidance); at the other end are diversified incumbents (Roche, GE HealthCare, Siemens Healthineers, AbbVie, Bayer, Natera) for which women's health is a minority of revenue and where theme exposure is diluted at the group level. Cyclicality is a live variable - Hologic's Breast Health fell 7.4% in fiscal Q2 2025 on mammography capital softness even as its diagnostics and surgical lines grew. This task did not retrieve valuation multiples (SEC filings and market-data pages were not fetchable in-session), so no multiple-based or relative-value conclusion is offered; the growth, margin-guidance and mix data points above are the public-eligible observations that frame the cycle. The honest limit: valuation dispersion is high and the theme is better expressed through differentiated exposure than a broad basket.

Catalysts

Dated catalysts

2025-02
Federal executive order directing officials to recommend policies protecting IVF access and reducing treatment costs.[4]
2025-10
Federal actions creating a new pathway for employers to offer fertility benefit packages and negotiating a lower fertility-drug price (TrumpRx).[4]
2025-11
FDA removal of the boxed warning on menopause hormone-therapy products (notably low-dose vaginal estrogen), a category-level tailwind for menopause therapeutics.[5]
2026-01-01
California SB 729 takes effect, requiring fully insured large-group plans to cover infertility treatment and IVF (delayed from July 2025).[4]
FY2026 (appropriations cycle)
Senate Appropriations USD 400 million NIH increase with report language directing uterine fibroids and PCOS research; monitor final enactment.[5]
2028 plan year
Virginia HB 328 adds IVF (up to three cycles per lifetime) and fertility treatment/diagnosis to its essential-health-benefits benchmark.[3]
Ongoing 2024-2028
Implementation of the NIH-Wide Strategic Plan for Research on the Health of Women 2024-2028 and SABV policy, directing sex-specific research and funding.[2]
Quarterly (2026)
Fertility/women's-health company prints: Progyny selling-season client and covered-lives adds, CooperSurgical fertility reacceleration, and Hologic breast-health capital cycle.[8]

Monitoring dashboard

quarterlyCoverage policies - state IVF/fertility mandates, federal employer-benefit pathway, CMS/Medicaid coverage, FDA labels
quarterlyDiagnostic adoption - NIPT/carrier-screening volumes and ASPs, HPV/cervical screening, mammography/AI imaging volumes
semi-annualSpecialist networks and capacity - fertility clinics/REIs, urogynecology, virtual specialty-care membership
quarterlyClinical-trial activity and FDA approvals - menopause (non-hormonal), endometriosis, uterine fibroids, PCOS
quarterlyPure-play operating metrics - Progyny covered lives/clients/cycles, CooperSurgical fertility growth, Hologic breast-health capital cycle
as availablePrivate-market signals - Maven Clinic and Axena Health funding rounds, valuations, coverage wins

Risks and disconfirming evidence

What breaks this thesis

Material risks

Reimbursement is discretionary and employer/state-budget-dependent; mandate momentum can stall (e.g., a governor vetoed a broader Medicaid fertility mandate) and Medicaid coverage remains rare (only ~3 states).
Customer-acquisition costs in direct-to-consumer femtech and virtual care can overwhelm care economics - an explicit thesis-break condition and a real risk for private platforms.
Category commoditization: NIPT, carrier screening and fertility consumables face ASP pressure and new entrants, eroding differentiation.
For many mapped names (Roche, GE HealthCare, Siemens, AbbVie, Bayer, Natera), women's health is a minority of revenue - group-level exposure is diluted and theme beta is muted.
Capital-equipment cyclicality (Hologic Breast Health -7.4% in fiscal Q2 2025) can depress imaging-linked exposure independent of the secular thesis.
Policy reversibility: federal fertility initiatives may not persist across administrations; FDA/label liberalization could face litigation or reversal.
Private-company opacity (Maven Clinic, Axena Health) limits verification of scale, unit economics and valuation.
Concentration and in-sourcing risk for benefits managers if large carriers replicate the model and compress take-rates.

Thesis-break conditions

Reimbursement remains weak: state fertility-mandate expansion stalls or retreats and Progyny covered-lives/client growth turns negative for two-plus consecutive quarters.
Care economics break: fertility-benefit or digital-platform gross margins compress materially, or Progyny's historically high client retention falls below ~95%, or private femtech marks down on CAC-driven losses.
Commoditization without differentiation: reproductive-testing average selling prices decline persistently (double-digit) with no offsetting proprietary content or volume, collapsing testing-segment economics.
Structural funding/attention reverses: the NIH women's-health research share continues falling below ~7% and directed appropriations language (fibroids/PCOS) is dropped, signaling de-prioritization.
Policy tailwinds fail to convert: FDA menopause-warning removal and new IVF mandates do not translate into measurable volume or covered-lives growth within 12-18 months.

Unresolved questions

Current (FY2025-FY2026) women's-health segment revenue and mix for Organon, Natera, Myriad Genetics, Bayer, AbbVie, Roche, GE HealthCare and Siemens Healthineers were not retrieved from primary filings this session and require verification.
Regulatory and launch status of Bayer's non-hormonal menopause candidate elinzanetant (and any peers) and the size of the menopause TAM it could capture.
Maven Clinic's latest valuation, covered lives, employer client count, and path to profitability (CAC vs LTV) - directly relevant to the care-economics thesis break.
Axena Health's commercial payer coverage breadth beyond VA/veteran access, revenue scale, and FDA clearance specifics.
Durability of federal fertility/IVF policy across administrations and whether state Medicaid coverage broadens beyond the current ~3 states.
Whether the November 2025 FDA menopause hormone-therapy warning removal materially increases prescribing volumes and category revenue.
Exact quantified women's-health TAM by sub-condition (endometriosis, fibroids, menopause, PCOS, pelvic health) from a primary/authoritative source rather than dispersed market-research estimates.

Researched company map

13 assessed companies

Every mapped company is assessed with evidence-qualified exposure. Materiality is claimed only where disclosure supports it.

Women's diagnostics and imaging - mammography/breast health, GYN surgical, and molecular diagnostics (cervical cytology and HPV).

Hologic HOLX

High and directly on-theme. Fiscal Q2 2025 (ended 2025-03-29) shows Breast Health USD 356.2 million (-7.4% YoY on mammography capital softness), GYN Surgical USD 162.5 million (+4.2%), and Diagnostics USD 453.6 million (+0.8%, including ThinPrep cervical cytology and Aptima HPV). The large majority of Hologic's revenue is women's-health oriented.

Evidence: Fetched Hologic fiscal Q2 2025 press release with divisional revenue and growth. Segment-level women's-health disclosure is explicit; capital-equipment cyclicality in Breast Health is a documented near-term drag.
Materiality: disclosed — Company discloses division-level revenue (Breast Health, GYN Surgical, Diagnostics) that is predominantly women's-health; figures fetched from the fiscal Q2 2025 release.
Investability view: The most diversified listed pure-ish women's-health franchise, spanning imaging, surgical and diagnostics; near-term growth is gated by the mammography capital cycle while diagnostics and surgical provide offset. Analytical read: high thematic centrality with cyclicality to monitor.

Next diligence: FY2025 10-K segment detail; ThinPrep/Aptima volumes and ASPs; Genius AI/3D mammography adoption and the breast-health capital replacement cycle.

Genetic diagnostics - hereditary cancer risk (MyRisk, including hereditary breast/ovarian), prenatal and carrier screening (Foresight/Prequel), alongside non-women's-health assays (e.g., GeneSight pharmacogenomics).

Myriad Genetics MYGN

Medium and partial. Hereditary breast/ovarian cancer risk, prenatal and carrier screening are women's-health-relevant, but the company is diversified across oncology and mental-health testing. Current segment revenue split was not retrieved this session.

Evidence: No Myriad-specific financials fetched this task (SEC filings not retrievable in-session; search budget exhausted). Product-line relevance is established from general public positioning, not from a fetched figure.
Materiality: not assessed — Women's-health share of revenue not established from a fetched primary source this session; only qualitative product relevance is supported.
Investability view: Enabling exposure through reproductive and hereditary-cancer testing, but diluted by non-women's-health lines; thematic weight cannot be confirmed without segment data.

Next diligence: Latest 10-Q/10-K: women's-health (prenatal/carrier/hereditary) revenue vs GeneSight/oncology; prenatal test volumes; reimbursement status for expanded screening.

Genetic testing - reproductive health (Panorama NIPT, Horizon carrier screening) alongside oncology (Signatera) and organ-health.

Natera NTRA

Medium and partial. Reproductive health is Natera's founding franchise, but recent growth has been oncology-led (Signatera), so women's-health is a declining share of the growth mix. Natera IR pages confirm the Panorama/Horizon and Signatera product lines; current segment revenue was not retrieved.

Evidence: Fetched Natera news/IR landing pages confirm product lines but not financials (pages were navigation-only; SEC filings not retrievable in-session).
Materiality: not assessed — Reproductive-health revenue and volume not established from a fetched primary figure this session; product relevance confirmed, magnitude not.
Investability view: Real but partial and possibly diminishing thematic exposure; the reproductive-testing category also carries ASP/commoditization risk. Confirmation of the reproductive-vs-oncology mix is required.

Next diligence: Latest 10-Q: reproductive-health revenue, Panorama NIPT volumes and ASP trends; competitive/pricing dynamics in NIPT and carrier screening.

Women's-health products - contraception (Nexplanon implant), Jada System (postpartum hemorrhage), fertility, plus biosimilars and established (legacy) brands.

Organon OGN

High by design - Organon was established as a women's-health-focused company (2021 Merck spin-off) - but a large share of revenue comes from established brands and biosimilars rather than the core women's-health growth engine. Current-quarter women's-health franchise revenue was not retrieved this session.

Evidence: No Organon-specific current financials fetched (newsroom URL returned 404/403; SEC filings not retrievable in-session; search budget exhausted). Structural women's-health orientation is well established publicly but current figures are unverified here.
Materiality: estimated — The company is structurally organized around women's health (a named reporting focus since spin-off), supporting an estimated material link; precise current segment figures were not fetched, so it is 'estimated' not 'disclosed'.
Investability view: Among the most thematically labeled listed names, but the investment read is complicated by legacy-brand loss-of-exclusivity and leverage; thematic upside concentrates in Nexplanon and newer assets like Jada.

Next diligence: Latest quarterly women's-health revenue (Nexplanon growth trajectory, Jada uptake), fertility contribution, LOE exposure and debt profile.

Fertility benefits platform - manages employer-sponsored fertility and family-building benefits (benefits + specialty pharmacy).

Progyny PGNY

High and pure-play. Q1 2025 revenue USD 324.0 million (+16.5% YoY), fertility benefit services USD 206.4 million (+22%), 532 clients, ~900,000 lives added in the recent selling season, 16,200 ART cycles (+9%); full-year 2025 revenue guidance USD 1.185-1.235 billion.

Evidence: Fetched Progyny Q1 2025 results (dated 2025-05-08 via IR/press). Directly captures the reimbursement-formalization thesis; policy tailwinds (state mandates, federal employer pathway) are supportive.
Materiality: disclosed — Pure-play fertility benefits company with disclosed revenue, client, covered-lives and cycle metrics fetched from the Q1 2025 release.
Investability view: The cleanest listed expression of fertility formalization; the swing variables are covered-lives/client growth, take-rate durability, and competitive in-sourcing by carriers. Analytical read: highest thematic purity, highest sensitivity to reimbursement and employer demand cycles.

Next diligence: 2026 selling-season client and covered-lives adds; utilization and take-rate trends; retention; competitive response from national carriers; Q1 2026 print (not reliably retrieved this session).

Fertility and women's-health devices/consumables via CooperSurgical (fertility ART media/consumables and devices; office & surgical women's-health incl. PARAGARD); balance of company is CooperVision contact lenses.

CooperCompanies COO

High within CooperSurgical, diluted at group level. Fiscal Q2 2025 (ended 2025-04-30): CooperSurgical USD 332.7 million (+8%), of which fertility USD 126.9 million (+3%) and office & surgical/women's-health USD 205.8 million (+13%); total company revenue USD 1,002.3 million, so women's-health/fertility is roughly a third of the company. FY2025 CSI guidance USD 1,347-1,359 million.

Evidence: Fetched CooperCompanies fiscal Q2 2025 release with the CooperSurgical fertility vs office/surgical breakout.
Materiality: disclosed — Company discloses CooperSurgical and its fertility vs office/surgical split; figures fetched from the fiscal Q2 2025 release.
Investability view: Direct fertility/women's-health device exposure, but group results are influenced by the larger CooperVision contact-lens business; thematic read depends on fertility reacceleration (only +3% in the quarter) and capital allocation between the two segments.

Next diligence: Fertility segment reacceleration drivers; PARAGARD trends; consumable pull-through; capital allocation between CVI and CSI; FY2026 guidance.

Women's-health therapeutics and devices - hormonal IUDs (Mirena, Kyleena, Jaydess) and a non-hormonal menopause pipeline candidate (elinzanetant).

Bayer BAYN.DE

Medium at the women's-health franchise level, low at the group level. The November 2025 FDA removal of the menopause hormone-therapy boxed warning is a category tailwind, and Bayer has a menopause pipeline asset; however, women's health is a small share of a diversified pharma/crop-science conglomerate, and Bayer-specific financials and the exact regulatory/launch status of elinzanetant were not retrieved this session.

Evidence: Category tailwind (menopause warning removal) fetched via SWHR; Bayer-specific financials and elinzanetant approval status not fetched (Bayer newsroom returned 403; search budget exhausted). elinzanetant status is therefore unverified here and flagged as an open question.
Materiality: not assessed — Women's-health revenue share and pipeline monetization not established from a fetched Bayer primary source this session; only a category-level regulatory tailwind is evidenced.
Investability view: Optionality on menopause and steady contraception franchises, but immaterial to a very large diversified group; thematic exposure is a small slice unless the menopause pipeline scales.

Next diligence: elinzanetant regulatory/launch status and menopause TAM; women's-health franchise sales; Mirena/Kyleena lifecycle and competitive dynamics.

Women's-health therapeutics - endometriosis (Orilissa/elagolix) and uterine fibroids (Oriahnn), within a portfolio dominated by immunology and aesthetics.

AbbVie ABBV

Low-to-medium at the franchise level, immaterial at the group level. Orilissa/Oriahnn address on-theme conditions (endometriosis, fibroids) that benefit from formalization and directed research funding, but they are small relative to AbbVie's immunology (Skyrizi/Rinvoq) and aesthetics revenue. AbbVie-specific women's-health financials were not retrieved this session.

Evidence: No AbbVie-specific figures fetched (SEC filings not retrievable in-session; search budget exhausted). Product relevance is established from general public knowledge, not a fetched figure.
Materiality: not assessed — Women's-health franchise revenue not established from a fetched primary source; magnitude is widely understood to be small relative to the group but was not quantified here.
Investability view: Thematic exposure exists via endometriosis/fibroid therapeutics but is not a group-level driver; relevant mainly as a category participant, not a pure-play.

Next diligence: Orilissa/Oriahnn revenue and growth; any women's-health pipeline expansion; sensitivity of the endometriosis/fibroid market to directed NIH funding.

Diagnostics and therapeutics - cervical cancer screening (cobas HPV) and broad diagnostics/pharma, with women's health a minor slice.

Roche ROG.SW

Low, consistent with the packet hypothesis. Roche participates in cervical cancer screening (HPV testing) and has women's-relevant assets, but women's health is a very small share of an extremely large diagnostics-plus-pharma group. No Roche-specific women's-health financials were retrieved this session.

Evidence: No Roche-specific figures fetched (search budget exhausted; corporate/primary pages not retrieved). Exposure is second-order and qualitative.
Materiality: not assessed — No fetched primary evidence quantifies women's-health materiality; the link is diluted/second-order and unquantified here.
Investability view: Diluted, second-order exposure; retain in the map only as a screening-infrastructure participant unless HPV/women's-health disclosures show materiality (unlikely at group scale).

Next diligence: HPV/cervical screening volumes and any dedicated women's-health disclosures - expected to be immaterial to group results.

Women's imaging - mammography (Senographe Pristina), breast ultrasound (Invenia ABUS), and maternal-infant care, within the broader imaging/PDx portfolio.

GE HealthCare GEHC

Medium at the product level, diluted at the group level. Women's-health imaging (mammography, breast ultrasound, AI) is a genuine product area competing with Hologic, but it is a sub-segment of GE HealthCare's large imaging franchise and is generally not separately broken out. No GE HealthCare-specific women's-health financials were retrieved this session.

Evidence: No GE HealthCare-specific figures fetched (newsroom returned 403; search budget exhausted). Product relevance is established qualitatively.
Materiality: not assessed — Women's-health imaging revenue is not separately disclosed and was not established from a fetched source; only qualitative product participation is supported.
Investability view: Credible women's-imaging participant but immaterial-to-modest at group level; thematic read is a small slice of a diversified imaging company, subject to the same capital cycle affecting Hologic Breast Health.

Next diligence: Any women's-health imaging revenue disclosure; AI mammography/ABUS positioning versus Hologic; imaging capital replacement cycle.

Women's imaging - mammography (Mammomat series) within a large imaging/diagnostics/Varian portfolio.

Siemens Healthineers SHL.DE

Medium at the product level, diluted at the group level. Mammography is an on-theme product line, but women's health is a small share of Siemens Healthineers' imaging/diagnostics/oncology group and is not separately broken out. No company-specific women's-health financials were retrieved this session.

Evidence: No Siemens Healthineers-specific figures fetched (search budget exhausted; primary pages not retrieved). Exposure is qualitative and product-level.
Materiality: not assessed — Women's-health imaging revenue is not separately disclosed and was not established from a fetched source this session.
Investability view: Mammography participant but immaterial-to-modest at group level; thematic exposure is indirect and cyclical, similar to other imaging incumbents.

Next diligence: Mammography installed base and refresh cycle; any women's-health disclosures; competitive positioning in breast imaging and AI.

Pelvic health - the Leva Pelvic Health System, a non-drug, non-surgical connected device/app for urinary and fecal incontinence and pelvic-floor rehabilitation.

Axena Health

Medium and focused, but early-stage and private. Axena is a dedicated pelvic-health company; the Leva system treats urinary and fecal incontinence, is supported by peer-reviewed evidence (including an RCT in Urogynecology), and gained access for female veterans through the VHA and VA Community Care in 2025-2026. It was accepted into AARP's AgeTech Collaborative (2025) and presented at FIGO 2025. No revenue, valuation or detailed FDA-clearance data were retrievable.

Evidence: Fetched Axena Health website confirming the Leva system, indications, VA/veteran access, clinical evidence and 2025 recognitions; the site did not disclose FDA-clearance specifics, reimbursement breadth or financials.
Materiality: not assessed — Private company with no fetched financials; qualitative product/coverage evidence exists but revenue-scale materiality cannot be assessed.
Investability view: A focused, evidence-backed pelvic-health play at an early commercialization stage; thematic fit is strong (formalizing a neglected condition) but scale, payer coverage breadth and unit economics are unverified.

Next diligence: Commercial payer coverage beyond VA; revenue scale and growth; FDA clearance specifics; funding runway and cap table.

Care delivery platform - virtual clinic for women's and family health (fertility, maternity, menopause, parenting/pediatrics) sold to employers and health plans.

Maven Clinic

High thematic fit but unverified in-session. Maven is widely regarded as the largest virtual women's-and-family-health platform and is directly aligned with the care-delivery and navigation layer of the thesis. However, this task did not retrieve current membership, employer-client, funding or valuation figures (news pages were JavaScript-rendered and returned no substantive content).

Evidence: Attempted to fetch Maven Clinic newsroom/homepage; pages returned navigation/loading content only, with no financial or membership data. No dated figure was obtained this session.
Materiality: not assessed — Private company; no fetched financial, membership or valuation data this session, so materiality cannot be assessed despite strong qualitative thematic alignment.
Investability view: Structurally a pure-play on women's/family digital care and the care-economics leg of the thesis; it is also the clearest test of the customer-acquisition-cost thesis break. Analytical read: high thematic centrality, but private and unverified here.

Next diligence: Latest funding round and valuation; covered lives and employer client count; revenue and path to profitability; CAC versus retention/LTV; any public-market intentions.

Source ledger

Every claim keeps its lineage

Primary sources are preferred; secondary sources are labeled. Access dates are recorded for every citation.

Overview of the National Institutes of Health Investment in Women's Health ResearchNational Academies of Sciences, Engineering, and Medicine (NCBI Bookshelf) / NIH data · primary · published 2024 · accessed 2026-07-22
NIH Office of Research on Women's Health (ORWH) - homepage and strategic prioritiesNIH Office of Research on Women's Health · primary · published 2026 (accessed) · accessed 2026-07-22
State Fertility Coverage Mandates Expand in 2026 Legislative Sessions (IVF and ART Laws)MultiState · secondary · published 2026-04-01 · accessed 2026-07-22
Fertility Care and IVF Access in 2025: State Legislation and Federal Policy HighlightsMultiState · secondary · published 2025-11-05 · accessed 2026-07-22
Looking Back, Moving Forward: Women's Health Research in 2025 and the Road AheadSociety for Women's Health Research (SWHR) · secondary · published 2025 · accessed 2026-07-22
Hologic Announces Financial Results for Second Quarter of Fiscal 2025Hologic, Inc. · primary · published 2025-04-30 · accessed 2026-07-22
CooperCompanies Announces Second Quarter 2025 ResultsThe Cooper Companies, Inc. (via GlobeNewswire) · primary · published 2025-05-29 · accessed 2026-07-22
Progyny, Inc. Announces First Quarter 2025 ResultsProgyny, Inc. (Investor Relations) · primary · published 2025-05-08 · accessed 2026-07-22
Axena Health - Leva Pelvic Health System (company website)Axena Health · primary · published 2026 (accessed) · accessed 2026-07-22
Women's Health Market Size & Share ReportGrand View Research · secondary · published 2025 · accessed 2026-07-22
Women's Health Market (size and forecast)Emergen Research · secondary · published 2025 · accessed 2026-07-22
Natera - Investor Relations / product overviewNatera, Inc. · primary · published 2026 (accessed) · accessed 2026-07-22

Evidence limitations

The shared WebSearch budget was exhausted mid-task (200/200), and SEC.gov filings plus several corporate newsrooms (Bayer, GE HealthCare, Organon) returned HTTP 403/404 to the fetch tool, so fresh primary financials could not be retrieved for Organon, Natera, Myriad, Bayer, AbbVie, Roche, GE HealthCare and Siemens Healthineers.
Market-size figures are third-party market-research estimates with wide dispersion (femtech ~USD 32-66 billion for 2025-2026; women's health ~USD 53-55 billion in 2025) and are secondary; scope and methodology differ across firms. Grand View/Emergen figures were surfaced via web search rather than a full-page fetch.
Several load-bearing policy claims (Feb 2025 IVF executive order, Oct 2025 federal employer fertility pathway, Nov 2025 FDA menopause-warning removal, FY2026 appropriations directives) are sourced to policy-tracking (MultiState) and advocacy (SWHR) secondary write-ups; primary texts (FDA notice, Federal Register, statutes, appropriations bill) are the recommended verification upgrade.
The NIH ORWH homepage did not disclose quantified funding; the NIH investment figures come from a National Academies overview covering data through FY2023-FY2025.
Progyny Q1 2026 specifics could not be reliably retrieved (source page timed out / returned 503); the dated Q1 2025 release (2025-05-08) is used, so the company data is one-to-a-few quarters stale relative to the 2026-07-22 research date.
Private companies (Maven Clinic, Axena Health) lack audited public financials; Maven's news pages returned no substantive fetched content, so its scale and valuation are unverified here.
No valuation multiples were fetched; valuation_context is qualitative and deliberately avoids relative-value conclusions.
elinzanetant's (Bayer) regulatory/launch status is referenced only as an open question because it was not confirmed from a fetched source.